Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study
Charles V. Pollack(Hospital of the University of Pennsylvania), Jeffrey I. Weitz(McMaster University Medical Centre), Menno V. Huisman(Leiden University Medical Center), Eva Kleine(Boehringer Ingelheim (Germany)), Thorsten Steiner(Heidelberg University), Jerrold H. Levy(Duke University), Robert Dubiel(Boehringer Ingelheim (Germany)), Fredrik Gruenenfelder(Boehringer Ingelheim (Germany)), Richard A. Bernstein(Northwestern University), Anastasia Ustyugova(Boehringer Ingelheim (Germany)), CW Kam(Boehringer Ingelheim (Germany)), Paul Reilly(Boehringer Ingelheim (United States)), Frank W. Sellke(Brown University)
Cited by 11
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2013|5.2k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
Cryptogenic Stroke and Underlying Atrial Fibrillation
|New England Journal of Medicine|2014|2.2k
Post-cardiac arrest syndrome: Epidemiology, pathophysiology, treatment, and prognostication
|Resuscitation|2008|1.5k